EGFR and non-small cell lung carcinoma: However, data regarding the consolidative SBRT for oligometastatic stage IV NSCLC patients with EGFR mutation during first line EGFR‐TKIs therapy are sparse.34, 37, 38, 39 Our study showed that the median PFS and OS of first line EGFR‐TKI therapy group were 26.4 months (95%CI:7.4‐52.4months) and 34.8 months (95%CI:18.8‐50.8 months), respectively.